NEW YORK, Oct. 8, 2024 /PRNewswire/ — Ubie Inc. is pleased to announce that it has received investment from Google in its latest funding round.

Ubie and Google investmentUbie and Google investment

Through this deal, the two companies agreed to help advance digital transformation of Japan’s healthcare system using digital innovations including generative AI.

About Ubie Inc.

Ubie is a health tech company with the mission of leveraging technology to guide people to the appropriate care. Our consumer service "Ubie" helps over 12 million people access appropriate medical care each month. "Ubie Medical Navigator" for healthcare institutions supports improving the quality of medical consultations in over 1,700 medical institutions nationwide, while "Ubie for Pharma" maximizes prescription opportunities in collaboration with pharmaceutical companies.

Since its founding in 2017, Ubie’s contributions through business activities, in collaboration with stakeholders, are estimated to have extended healthy life expectancy by over 27,000 years and created an economic value exceeding 150 billion yen. Additionally, Ubie established a U.S. subsidiary in 2022 and is working on expanding its presence there.

Learn more about our vision and work at https://ubiehealth.com/company or try our free Symptom Checker at https://ubiehealth.com/.

Source link

This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network
You May Also Like

LEPAS L4 Makes Its Overseas Debut, Opening a New Gateway to "Exquisite Life and Self-pleasing Travel" for Global Youth

WUHU, China, Aug. 8, 2025 /PRNewswire/ — Recently, the L4, the debut model…

Cambrex to Expand Stability Storage Business with New Facility in Durham, North Carolina

EAST RUTHERFORD, N.J., July 8, 2024 /PRNewswire/ — Cambrex today announced the…

Bambusa Therapeutics Presented Positive Results from the Phase 1 Multiple Ascending Dose Trial of BBT001 at the 2026 American Academy of Dermatology (AAD) Annual Meeting

– Bambusa’s lead product candidate, BBT001 is a next-generation long-acting bispecific antibody…